INOVIO Announces FDA's Orphan Drug Designation For INO-3107 - Quick Facts

(RTTNews) - INOVIO (INO) said the FDA granted orphan drug designation for INO-3107, the company's DNA medicine being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory papillomatosis.

The open-label, multicenter INO-3107 Phase 1/2 trial is currently open to enrollment to recruit 63 subjects in the U.S. and will evaluate the efficacy, safety, tolerability, and immunogenicity of INO-3107 in subjects with HPV 6 and/or 11-associated recurrent respiratory papillomatosis who have required at least two surgical interventions per year for the past three years for the removal of associated papilloma.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More